公开(公告)号：US20170267634A1

公开(公告)日：2017-09-21

申请号：US15504018

申请日：2015-09-11

Applicant: SUNSHINE LAKE PHARMA CO., LTD.

Inventor： Yingjun ZHANG ,  Tianzhu YU ,  Bing LIU ,  Xiangyu ZHANG ,  Shiguo ZHANG ,  Changchung CHENG ,  Jiancun ZHANG

IPC: C07D209/14 ,  A61K31/454 ,  C07D401/14 ,  A61K31/4709 ,  A61K45/06 ,  C07D401/12 ,  C07D471/04 ,  A61K31/4375 ,  C07D403/12 ,  A61K31/498 ,  C07D401/04 ,  A61K31/405

CPC classification number: C07D209/14 ,  A61K31/405 ,  A61K31/4375 ,  A61K31/454 ,  A61K31/4709 ,  A61K31/498 ,  A61K45/06 ,  C07B2200/13 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D401/14 ,  C07D403/12 ,  C07D471/04

Abstract: The compounds of Formula (I) which can be used as CRTH2 receptor antagonists are provided. The compounds of Formula (I) can be used in the treatment and prevention of asthma, allergic rhinitis and atopic dermatitis, as well as other diseases mediated by prostaglandin D2 (PGD2) at the CRTH2 receptor.